Concepció Marin1, Dolores Vilas2, Cristóbal Langdon3,4, Isam Alobid3,4,5, Mauricio López-Chacón3,4, Antje Haehner6, Thomas Hummel6, Joaquim Mullol7,8,9. 1. INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CELLEX, Department 2B, Villarroel 170, 08036, Barcelona, Catalonia, Spain. cmarin@clinic.cat. 2. Neurodegenerative Diseases Unit, Neurology Service, University Hospital Germans Trias i Pujol, Badalona, Catalonia, Spain. 3. INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CELLEX, Department 2B, Villarroel 170, 08036, Barcelona, Catalonia, Spain. 4. Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Catalonia, Spain. 5. Centre for Biomedical Investigation in Respiratory Diseases (CIBERES), Barcelona, Spain. 6. Smell and Taste Clinic, Department of Otorhinolaryngology, Technische Universität Dresden, Dresden, Germany. 7. INGENIO, IRCE, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CELLEX, Department 2B, Villarroel 170, 08036, Barcelona, Catalonia, Spain. jmullol@clinic.cat. 8. Rhinology Unit and Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Catalonia, Spain. jmullol@clinic.cat. 9. Centre for Biomedical Investigation in Respiratory Diseases (CIBERES), Barcelona, Spain. jmullol@clinic.cat.
Abstract
PURPOSE OF REVIEW: The sense of smell is today one of the focuses of interest in aging and neurodegenerative disease research. In several neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, the olfactory dysfunction is one of the initial symptoms appearing years before motor symptoms and cognitive decline, being considered a clinical marker of these diseases' early stages and a marker of disease progression and cognitive decline. Overall and under the umbrella of precision medicine, attention to olfactory function may help to improve chances of success for neuroprotective and disease-modifying therapeutic strategies. RECENT FINDINGS: The use of olfaction, as clinical marker for neurodegenerative diseases is helpful in the characterization of prodromal stages of these diseases, early diagnostic strategies, differential diagnosis, and potentially prediction of treatment success. Understanding the mechanisms underlying olfactory dysfunction is central to determine its association with neurodegenerative disorders. Several anatomical systems and environmental factors may underlie or contribute to olfactory loss associated with neurological diseases, although the direct biological link to each disorder remains unclear and, thus, requires further investigation. In this review, we describe the neurobiology of olfaction, and the most common olfactory function measurements in neurodegenerative diseases. We also highlight the evidence for the presence of olfactory dysfunction in several neurodegenerative diseases, its value as a clinical marker for early stages of the diseases when combined with other clinical, biological, and neuroimage markers, and its role as a useful symptom for the differential diagnosis and follow-up of disease. The neuropathological correlations and the changes in neurotransmitter systems related with olfactory dysfunction in the neurodegenerative diseases are also described.
PURPOSE OF REVIEW: The sense of smell is today one of the focuses of interest in aging and neurodegenerative disease research. In several neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, the olfactory dysfunction is one of the initial symptoms appearing years before motor symptoms and cognitive decline, being considered a clinical marker of these diseases' early stages and a marker of disease progression and cognitive decline. Overall and under the umbrella of precision medicine, attention to olfactory function may help to improve chances of success for neuroprotective and disease-modifying therapeutic strategies. RECENT FINDINGS: The use of olfaction, as clinical marker for neurodegenerative diseases is helpful in the characterization of prodromal stages of these diseases, early diagnostic strategies, differential diagnosis, and potentially prediction of treatment success. Understanding the mechanisms underlying olfactory dysfunction is central to determine its association with neurodegenerative disorders. Several anatomical systems and environmental factors may underlie or contribute to olfactory loss associated with neurological diseases, although the direct biological link to each disorder remains unclear and, thus, requires further investigation. In this review, we describe the neurobiology of olfaction, and the most common olfactory function measurements in neurodegenerative diseases. We also highlight the evidence for the presence of olfactory dysfunction in several neurodegenerative diseases, its value as a clinical marker for early stages of the diseases when combined with other clinical, biological, and neuroimage markers, and its role as a useful symptom for the differential diagnosis and follow-up of disease. The neuropathological correlations and the changes in neurotransmitter systems related with olfactory dysfunction in the neurodegenerative diseases are also described.
Authors: Michelle E Fullard; Baochan Tran; Lama M Chahine; James F Morley; Sharon X Xie; Jon B Toledo; Christi Scordia; Carly Linder; Rachael Purri; Daniel Weintraub; John E Duda Journal: Parkinsonism Relat Disord Date: 2016-02-19 Impact factor: 4.891
Authors: María Gutièrrez-Mecinas; Carlos Crespo; José Miguel Blasco-Ibáñez; Francisco Javier Gracia-Llanes; Ana Isabel Marqués-Marí; Juan Nácher; Emilio Varea; Francisco José Martínez-Guijarro Journal: Eur J Neurosci Date: 2005-09 Impact factor: 3.386
Authors: Pietro Tiraboschi; Larry A Hansen; Michael Alford; Annette Merdes; Eliezer Masliah; Leon J Thal; Jody Corey-Bloom Journal: Arch Gen Psychiatry Date: 2002-10
Authors: Frederick Yoo; Zachary M Soler; Jennifer K Mulligan; Kristina A Storck; Jensine M Lamira; Whitney N Pasquini; Jonathan B Hill; Tegan E Noonan; Brandon J Washington; Rodney J Schlosser Journal: Int Forum Allergy Rhinol Date: 2019-08-23 Impact factor: 3.858
Authors: Jesse K Siegel; Xiandao Yuan; Kristen E Wroblewski; Martha K McClintock; Jayant M Pinto Journal: J Gerontol A Biol Sci Med Sci Date: 2021-02-25 Impact factor: 6.053
Authors: Karla C M Costa; Tamires A V Brigante; Gabriel G Fernandes; Davi S Scomparin; Franciele F Scarante; Danielle P de Oliveira; Alline C Campos Journal: eNeuro Date: 2021-06-02